Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression data from human endometrial cancer cells treated with siRNA targeting Efp

ABSTRACT: Gene expression data from human endometrial cancer cells treated with siRNA targeting Efp

PROVIDER: PRJNA484902 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression data from human endometrial cancer cells treated with siRNA targeting Efp

Project description:To examine the role of Efp in endometrial cancer cells, Ishikawa and HEC-1A cells were treated with siRNA targeting Efp (siEfp) or control siRNA (siControl). Microarray analysis showed that Efp knockdown represses NF-κB-signaling pathway-associated genes.

2018-11-20 | GSE118228 | GEO

Gene expression data from endometrial cancer patient-derived cells (EDC-PDCs) treated with Efp siRNA

Project description:To examine the role of Efp in endometrial cancer, patient-derived cells were treated with siRNA targeting Efp (siEfp) or control siRNA (siControl). siRNA-mediated Efp silencing resulted in suppressed spheroid proliferation and altered gene expression profile, featuring downregulation of genes related to cell cycle and inflammation/immune responses. This study provides an insight into alternative endometrial cancer therapeutic strategies targeting Efp.

2024-01-13 | GSE164724 | GEO

Transcriptome of human decidual cells treated by siRNA targeting FOXO1

Project description:Here we report the gene expression profile of in vitro cultured human endometrial stromal cells treated with siRNA targeting FOXO1 piror to eutherian differentiation media exposure. The eutherian differentiation media contains cyclic AMP (cAMP) analogue 8-Br-cAMP and the progesterone (P4) analogue medroxyprogesterone acetate (MPA).

2018-06-21 | GSE115832 | GEO

Prostate cancer cell lines: non-targeting siRNA versus SChLAP1-siRNA treated

Project description:SChLAP1 is a novel long non-coding RNA expressed in prostate cancer. Here we performed transcriptional profiling of the prostate cancer cell lines LNCaP and 22Rv1 comparing non-targeting siRNA treatment versus SChLAP1-siRNA treatment. Goal was to determine the effect of SChLAP1 knockdown on gene expression in prostate cancer. Two-condition experiment: non-targeting siRNA versus SChLAP1 siRNA treated cells. Biological replicates: 1 control replicate, 2 treatment replicates. Technical replicates: 3 replicates per SChLAP1 siRNA. Cell lines: 22Rv1 and LNCaP.

2013-07-20 | E-GEOD-40383 | biostudies-arrayexpress

Cynomolgus macaques treated with Divalent-siRNA (Di-siRNA) targeting Huntingtin gene

Project description:Cynomolgus macaques treated with Divalent-siRNA (Di-siRNA) targeting Huntingtin gene

| PRJNA534060 | ENA

Gene expression data from human breast cancer MDA-MB-231 cells treated with siRNA targeting NONO

Project description:To examine the role of NONO in estrogen-independent breast cancer, MDA-MB-231 cells were treated with siRNA targeting NONO or control siRNA (siControl). Microarray analysis revealed NONO-regulated genes in MDA-MB-231 cells.

2020-01-13 | GSE132742 | GEO

Gene expression data from human breast cancer MCF-7 cells treated with siRNA targeting PSF or NONO

Project description:To examine the role of PSF and NONO in estrogen-dependent breast cancer, MCF-7 cells were treated with siRNA targeting PSF, NONO or control siRNA (siControl). Microarray analysis revealed PSF- or NONO-regulated genes in MCF-7 cells.

2020-01-13 | GSE132743 | GEO

Gene expression data from endometrial cancer patient-derived cells (EDC-PDCs) treated with Efp siRNA

Project description:Gene expression data from endometrial cancer patient-derived cells (EDC-PDCs) treated with Efp siRNA

| PRJNA691735 | ENA

Gene expression in human endometrial cancer tissues and serous papillary endometrial cancer cell line, SPAC-1L, treated by STAT1-siRNA and/or IFN-gamma

Project description:Endometrial cancer is one of the most common gynecologic malignancies, and patients with high grade disease, especially serous papillary subtype (SPEC) are often related to the poor outcomes. Recent genome-wide analyses have revealed that SPEC exhibits gene expression profiles that are distinct from the endometrioid histologic subtype; therefore, it is important to identify the SPEC driver genes or pathways responsible for the inherently aggressive phenotypes and to develop SPEC-specific therapies to target these driver genes or pathways. Through array-based analysis and immunohistochemical staining of human endometrial cancer tissue, STAT1 is identified high expressed, and can distinguish SPEC from other subtypes of endometrial cancer. In vitro and in vivo experiments show STAT1 role as a pro-survival factor in SPEC. STAT1 was identified as a master gene modulating “transcriptional pro-survival pathways” to enhance multiple malignant characteristics These finding may suggest that targeting of STAT1, the SPEC driver gene, may provide the means to improve poor outcomes for patients with SPEC. We used microarrays to clarify the changes of gene expression along with STAT1-siRNA treatment and to confirm whether there are any changes on genes expression related to STAT1 pathway. We also used the microarray data to clarify genes signatures which can distinguish subtype of human endometrial cancers.

2014-03-20 | E-GEOD-56026 | biostudies-arrayexpress

Expression data from Neuro2a cells treated with siRNA targeting to Cpeb1 mRNA.

Project description:Expression data from Neuro2a cells treated with siRNA targeting to Cpeb1 mRNA.

| PRJNA615678 | ENA